RNA Interference
Sarepta Sells $174 Million Stake in Arrowhead to Fund Milestone Payment Amid Cash Crunch
Sarepta Therapeutics; Arrowhead Pharmaceuticals; cash crunch; stake sale; milestone payment; RNAi collaboration; SRP-1003; myotonic dystrophy; private block trade
Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million
Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments
Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio
Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
ARO-C3, IGA Glomerulonephritis, RNA Interference
Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy
Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases
Bausch + Lomb Enters Strategic Collaboration with City Therapeutics for RNAi-Based Eye Disease Treatment
Bausch + Lomb, City Therapeutics, RNAi, eye disease, geographic atrophy, age-related macular degeneration, strategic collaboration
Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $10 Billion Collaboration for Rare Disease Treatments
Sarepta Therapeutics, Arrowhead Pharmaceuticals, RNAi, Rare Diseases, Genetic Medicine, Collaboration Agreement, Biotech, Pharmaceutical Industry
Revolutionizing AATD Treatment: Emerging Therapies to Replace Augmentation Therapy
Alpha-1 Antitrypsin Deficiency (AATD), Genetic Disorder, New Therapies, Augmentation Therapy, RNA Interference (RNAi), Gene Editing, CRISPR
RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup
RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup
Arrowhead Pharmaceuticals Highlights Key Pancreatitis Data from Phase 3 Lipid Disease Study to Distinguish Itself from Ionis
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Plozasiran, Olezarsen, Severe Hypertriglyceridemia (SHTG), Familial Chylomicronemia Syndrome (FCS), Acute Pancreatitis, RNAi Therapy, Triglyceride Reduction